Link William Phd Purchases Shares of TARS
Link William Phd acquired 2,954 shares of TARS on June 12, 2026, as part of insider trading activity.
Key Points
- Link William Phd bought 2,954 shares of TARS on June 12, 2026, with no planned transaction code.
- TARS shares traded at $61.85, with a strong buy consensus among analysts and price targets reaching $105.
- Institutional investors like Deep Track Capital and Janus Henderson Group adjusted their TARS holdings significantly.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, Link William Phd made a move in the stock market by purchasing 2,954 shares of TARS. This insider transaction was not pre-planned, indicating a direct acquisition of shares. The purchase adds to the ongoing activity among TARS insiders.
Other Institutional Activity in TARS
Several institutional investors have been adjusting their positions in TARS. Deep Track Capital increased its holdings by 595,966 shares, ending with 3.6 million shares valued at approximately $252.54 million. Meanwhile, BlackRock, Inc. reduced its stake by 237,945 shares, bringing its total to about 3.55 million shares worth $249.22 million. RTW Investments, LP made a smaller addition of 10,705 shares, now holding 3.35 million shares valued at $234.72 million. Paradigm Biocapital Advisors LP maintained its position with 2.56 million shares valued at $179.74 million. Janus Henderson Group added 310,638 shares, reaching 2.24 million shares worth $157.22 million.
Tarsus Pharmaceuticals, Inc. Stock Down 13.8%
Shares of TARS were trading at $61.85. The stock has been under the spotlight with several analysts maintaining a positive outlook. The market activity and institutional interest reflect the ongoing confidence in TARS's performance.
$TARS stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.
On June 12, 2026, insider transactions included several buys and sells. Wendy Yarno bought 2,954 shares, while Bhaskar Chaudhuri and Andrew Goldberg each sold 2,954 shares. These transactions were not part of any planned trading programs.
Analysts Set New Price Targets
Analyst firms have shown a strong buy consensus for TARS. On May 4, 2026, HC Wainwright & Co. reiterated its buy rating with a price target of $88. Oppenheimer and Guggenheim maintained their buy ratings earlier in the year, with targets of $105 and $90, respectively. Barclays initiated coverage with a buy rating and a $100 target in December 2025.
Bottom Line
Link William Phd's purchase of TARS shares highlights ongoing insider interest in the company. With analysts maintaining high price targets and institutional investors adjusting their positions, TARS remains a closely watched stock. These insider transactions provide a glimpse into the confidence levels of those closest to the company, although they do not necessarily predict future stock performance.
Get Tarsus Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TARS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.